News
Globaldata's analysis focuses on three key indicators, which include HTA outcomes in the 5EU and the entry of newly priced ...
Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from ...
Haya Therapeutics has secured $65m in Series A funding to expedite the clinical development of HTX-001 for treating heart ...
HLS Therapeutics has signed an agreement with Esperion Therapeutics for commercialising Nexletol and Nexlizet in Canada.
BioVaxys Technology and Sona Nanotech have signed an agreement to develop cancer therapeutics, utilising the DPX platform ...
Viralgen has partnered biotech company Trogenix, aiming to accelerate the development of gene therapy for glioblastoma.
The Vivo Opportunity Fund has already catalysed a plethora of medicine development via biotech investments in its first two ...
The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement genAI across the agency by 30 June ...
Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and ...
ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results